Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1373/clinchem.2015.253237 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PTEN loss in glioma cell lines leads to increased extracellular vesicle biogenesis and PD-L1 cargo in a PI3K-dependent manner.
J Biol Chem
December 2024
Department of Molecular Medicine, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, USA; Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY, 14853, USA. Electronic address:
Phosphatase and Tensin Homologue (PTEN) is one of the most frequently lost tumor suppressors in cancer and the predominant negative regulator of the PI3K/AKT signaling axis. A growing body of evidence has highlighted the loss of PTEN with immuno-modulatory functions including the upregulation of the programmed death ligand-1 (PD-L1), an altered tumor derived secretome that drives an immunosuppressive tumor immune microenvironment (TIME), and resistance to certain immunotherapies. Given their roles in immunosuppression and tumor growth, we examined whether the loss of PTEN would impact the biogenesis, cargo, and function of extracellular vesicles (EVs) in the context of the anti-tumor associated cytokine interferon-γ (IFN-γ).
View Article and Find Full Text PDFApigenin inhibits epithelial mesenchymal transition in renal tubular epithelial cells through PI3K/AKT and NF-κB pathways for treating renal fibrosis.
Gene
January 2025
Department of Pathology, Henan Medical College, Zhengzhou, China. Electronic address:
Renal fibrosis is a crucial factor in the progression of chronic kidney diseases. Previous studies have suggested that apigenin (API) has potential in ameliorating renal fibrosis, but its therapeutic mechanism remains unclear. This study aims to elucidate the mechanisms by which API treats renal fibrosis using network pharmacology and experimental validation.
View Article and Find Full Text PDFCHS-Ⅳa activates the IGF1R/PI3K signal pathway with inhibited pyroptosis of endometrial stromal cells and progress of endometriosis.
Int Immunopharmacol
December 2024
Department of Obstetrics and Gynecology, Zhangjiagang Hospital Affiliated to Soochow University, Zhangjiagang, Jiangsu, 215006, China. Electronic address:
Ethnopharmacological Relevance: Chikusetsusaponin IVa (CHS IVa) as a natural extract from the Panax japonicus (T.Nees) C.A.
View Article and Find Full Text PDFGRK2 Protein Mediates the ANRIL, a lncRNA, to Affect the Proliferation and Apoptosis of Kasumi-1 Cells.
Front Biosci (Landmark Ed)
October 2024
Center for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, 550004 Guiyang, Guizhou, China.
Background: A long non-coding RNAs (LncRNAs) called antisense noncoding RNA in the INK4 locus (), has emerged as substantial regulators of cell survival in acute myeloid leukemia (AML). However, its speciffc and potential mechanism is uncertain in AML. In this research, we investigated the role of in cell proliferation, apoptosis, and the underlying mechanism in AML cells.
View Article and Find Full Text PDFGenome-wide CRISPR/Cas9 screen identifies SLC39A9 and PIK3C3 as crucial entry factors for Ebola virus infection.
PLoS Pathog
August 2024
School of Basic Medical Sciences, Tsinghua University, Beijing, China.
Article Synopsis
- The Ebola virus (EBOV) poses a serious global health threat, highlighted during the 2013-2016 outbreak in West Africa, and there is a pressing demand for more effective antiviral drugs and understanding of how EBOV interacts with host cells.
- Using a specialized cell culture model, researchers conducted a genome-wide CRISPR/Cas9 screen, identifying two key host factors, PIK3C3 and SLC39A9, that play critical roles in facilitating EBOV entry into cells.
- The study reveals that PIK3C3 is essential for the internalization of EBOV, while SLC39A9 acts both as an attachment factor and an adaptor protein, indicating potential targets for new antiviral therapies against
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!